NASDAQ · CORT
Healthcare · Biotechnology
$118.10
Up+$0.93 (+0.79%)
Updated Aug 19, 2026, 7:44 AM
SID Score
5.9/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
CORT closed at $118.10 after 21 trading sessions, up 23.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $116.595 | $119.95 | $116.595 | $118.10 | 804.03K |
| Aug 17, 2026 | $115.00 | $117.49 | $114.385 | $117.17 | 541.1K |
| Aug 14, 2026 | $110.61 | $114.899 | $110.085 | $114.47 | 728.92K |
| Aug 13, 2026 | $112.53 | $113.00 | $110.23 | $110.51 | 740.46K |
| Aug 12, 2026 | $110.89 | $114.00 | $110.6001 | $112.18 | 662.99K |
| Aug 11, 2026 | $114.13 | $114.71 | $111.66 | $111.86 | 699.95K |
| Aug 10, 2026 | $110.84 | $114.6279 | $110.0548 | $114.23 | 1.26M |
| Aug 7, 2026 | $108.25 | $110.79 | $108.075 | $110.77 | 769.04K |
| Aug 6, 2026 | $111.00 | $111.00 | $107.32 | $107.95 | 761.83K |
| Aug 5, 2026 | $111.00 | $111.96 | $109.21 | $110.69 | 846.86K |
| Aug 4, 2026 | $113.00 | $113.455 | $109.03 | $109.80 | 1.27M |
| Aug 3, 2026 | $114.16 | $115.00 | $109.00 | $112.80 | 1.69M |
| Jul 31, 2026 | $118.11 | $118.53 | $111.79 | $114.49 | 1.84M |
| Jul 30, 2026 | $112.00 | $122.21 | $104.75 | $118.32 | 4.5M |
| Jul 29, 2026 | $94.84 | $96.60 | $91.54 | $92.95 | 1.55M |
| Jul 28, 2026 | $90.89 | $94.32 | $90.00 | $94.19 | 823.42K |
| Jul 27, 2026 | $91.595 | $93.35 | $90.12 | $91.12 | 1.42M |
| Jul 24, 2026 | $96.76 | $97.63 | $94.57 | $95.36 | 1M |
| Jul 23, 2026 | $90.97 | $97.05 | $90.43 | $96.66 | 981.14K |
| Jul 22, 2026 | $95.18 | $95.65 | $90.77 | $90.88 | 1.38M |
| Jul 21, 2026 | $92.00 | $95.79 | $91.21 | $95.65 | 839.33K |
The latest Smart Investors Daily articles mentioning CORT.
CORT research
Company profile and research snapshot.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | Canaccord Genuity | Buy | — |
| Jul 30, 2026 | Piper Sandler | Overweight | — |
| Jul 30, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 29, 2026 | Canaccord Genuity | Buy | — |
| Jul 27, 2026 | Wolfe Research | Underperform | — |
No generated briefing is available yet.
SeekingAlpha · Jul 31, 2026
Corcept Therapeutics (CORT) rated Hold: LIFYORLIâs strong launch is priced in; pipeline offers upside but risks persist. Click here to read more.
Benzinga · Jul 30, 2026
Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $88 to $165.
Benzinga · Jul 30, 2026
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $150 to $161.
Benzinga · Jul 30, 2026
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $95 to $165.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CORT.
